Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04251533
Title Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss (EPIK-B3)
Acronym EPIK-B3
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | ITA | GBR | FRA | ESP | DEU | AUT | AUS

Facility Status City State Zip Country Details
University Of California Los Angeles Santa Monica Location Los Angeles California 90095 United States Details
Hematology and Oncology Clinic SC Baton Rouge Louisiana 70809 United States Details
Mayo Clinic Rochester Mayo - Roch. Rochester Minnesota 55905 United States Details
Park Nicollet Institute Dept Onc Saint Louis Park Minnesota 55416 United States Details
SCRI Oncology Partners Tennessee Oncology (3) Nashville Tennessee 37203 United States Details
Novartis Investigative Site Caba Buenos Aires C1125ABD Argentina Details
Novartis Investigative Site Rosario Santa Fe S2000KZE Argentina Details
Novartis Investigative Site Melbourne Victoria 3000 Australia Details
Novartis Investigative Site Nedlands Western Australia 6009 Australia Details
Novartis Investigative Site Innsbruck Tyrol 6020 Austria Details
Novartis Investigative Site Leoben A 8700 Austria Details
Novartis Investigative Site Barretos SP 14784 400 Brazil Details
Novartis Investigative Site Sao Paulo SP 01317-002 Brazil Details
Novartis Investigative Site Sao Paulo SP 04014-002 Brazil Details
Novartis Investigative Site Plovdiv 4004 Bulgaria Details
Novartis Investigative Site Hefei Anhui 230001 China Details
Novartis Investigative Site Shijiazhuang Hebei 050011 China Details
Novartis Investigative Site Changsha Hunan 410013 China Details
Novartis Investigative Site Nanjing Jiangsu 210029 China Details
Novartis Investigative Site Chang Chun Jilin 130021 China Details
Novartis Investigative Site Shengyang Liaoning 110042 China Details
Novartis Investigative Site Chengdu Sichuan 610041 China Details
Novartis Investigative Site Hangzhou Zhejiang 310016 China Details
Novartis Investigative Site Dalian 116000 China Details
Novartis Investigative Site Shanghai 200025 China Details
Novartis Investigative Site Shenyang 110001 China Details
Novartis Investigative Site Tianjin 300480 China Details
Novartis Investigative Site Bogota 110221 Colombia Details
Novartis Investigative Site Zagreb 10000 Croatia Details
Novartis Investigative Site Saint-Cloud Hauts De Seine 92210 France Details
Novartis Investigative Site Angers Cedex 02 49055 France Details
Novartis Investigative Site Saint-Herblain Cédex 44805 France Details
Novartis Investigative Site Villejuif 94800 France Details
Novartis Investigative Site Dresden 01307 Germany Details
Novartis Investigative Site Essen 45136 Germany Details
Novartis Investigative Site Leipzig 04103 Germany Details
Novartis Investigative Site Budapest 1062 Hungary Details
Novartis Investigative Site Faridabad Haryana 121 001 India Details
Novartis Investigative Site Mumbai Maharashtra 400056 India Details
Novartis Investigative Site Vellore Tamil Nadu 632 004 India Details
Novartis Investigative Site Hyderabad Telangana 500034 India Details
Novartis Investigative Site Tel Aviv 6423906 Israel Details
Novartis Investigative Site Meldola FC 47014 Italy Details
Novartis Investigative Site Roma RM 00128 Italy Details
Novartis Investigative Site Napoli 80131 Italy Details
Novartis Investigative Site Seoul 03080 Korea, Republic of Details
Novartis Investigative Site Seoul 05505 Korea, Republic of Details
Novartis Investigative Site Seoul 06351 Korea, Republic of Details
Novartis Investigative Site Petaling Jaya Selangor 46050 Malaysia Details
Novartis Investigative Site Kuala Lumpur 59100 Malaysia Details
Novartis Investigative Site Monterrey Nuevo Leon 64460 Mexico Details
Novartis Investigative Site Oslo NO 0450 Norway Details
Novartis Investigative Site Trujillo La Libertad 13011 Peru Details
Novartis Investigative Site Gdynia 81 519 Poland Details
Novartis Investigative Site Opole 45-061 Poland Details
Novartis Investigative Site Poznan 61 485 Poland Details
Novartis Investigative Site Arkhangelsk 163045 Russian Federation Details
Novartis Investigative Site Chelyabinsk 454048 Russian Federation Details
Novartis Investigative Site Moscow 117997 Russian Federation Details
Novartis Investigative Site Moscow 123056 Russian Federation Details
Novartis Investigative Site Pushkin Saint Petersburg 196603 Russian Federation Details
Novartis Investigative Site Bratislava Slovak Republic 83310 Slovakia Details
Novartis Investigative Site Bratislava 812 50 Slovakia Details
Novartis Investigative Site Kosice 041 91 Slovakia Details
Novartis Investigative Site Ljubljana 1000 Slovenia Details
Novartis Investigative Site Port Elizabeth Western Cape 6045 South Africa Details
Novartis Investigative Site Johannesburg 2196 South Africa Details
Novartis Investigative Site Alicante Comunidad Valenciana 03010 Spain Details
Novartis Investigative Site Badajoz Extremadura 06080 Spain Details
Novartis Investigative Site Palma De Mallorca Islas Baleares 07120 Spain Details
Novartis Investigative Site Lausanne 1011 Switzerland Details
Novartis Investigative Site Taipei 10002 Taiwan Details
Novartis Investigative Site Taipei 10449 Taiwan Details
Novartis Investigative Site Istanbul 34722 Turkey Details
Novartis Investigative Site Istanbul 35100 Turkey Details
Novartis Investigative Site Nottingham NG5 1PB United Kingdom Details
Novartis Investigative Site Oxford OX3 7LJ United Kingdom Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field